CD34 and acute graft versus host disease: Like the findings from the entire cohort, CD34+ cell dose (both as a continuous variable and dichotomized as low vs. high group) was not associated with grade 3–4 acute GVHD or moderate to severe chronic GVHD in either the MRDpos or MRDneg subset of patients.